- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.05. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 03.04. | Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans | 244 | GlobeNewswire (Europe) | HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026... ► Artikel lesen | |
| 11.03. | IMPACT BIOMEDICAL INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 04.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 9 | SEC Filings |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| IBIO | 1,163 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,317 | +1,35 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,260 | +1,29 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 2,727 | +0,44 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| MANNKIND | 3,395 | 0,00 % | MannKind-Aktie: Biotech-Chance mit neuen Wachstumstreibern | Die MannKind-Aktie steht nach zwei wichtigen FDA-Zulassungen vor einer neuen Wachstumsphase. Bei einer Marktkapitalisierung von rund 1,24 Milliarden US-Dollar könnte der Markt das langfristige Potenzial... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,064 | +0,66 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| IMMUNIC | 13,485 | -2,56 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11.08.2026 / 12:30 CET/CEST
The... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 6,910 | -0,29 % | TD Cowen raises Iovance Biotherapeutics price target on sales outlook | ||
| MOLECULIN BIOTECH | 0,640 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial | Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in September... ► Artikel lesen | |
| GENPREX | 3,700 | +0,82 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| MESOBLAST | 1,560 | +2,33 % | Eli Lilly zahlt bis zu 7 Milliarden für Zelltherapie - warum jetzt auch bei Mesoblast der nächste große Test beginnt |
Das Unternehmen IMPACT BIOMEDICAL INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,000 (+0,02 %) liegt der Kurs bei 0,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPACT BIOMEDICAL INC finden Sie auf Wallstreet Online.